ArticleDrug design, development and therapy2026
Indication Expansion Dynamics and Trial Characteristics of Novel Multi-Indication Anti-Cancer Drugs in China (2000-2024): A Cross-Sectional Study.
Article in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Beyond Indication Expansion: Aligning Evidence, Reimbursement, and Access in Multi-Indication Oncology Drugs [Letter].Drug design, development and therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To perform a cross-sectional analysis of the indication expansion trends and pivotal trial features of novel multi-indication anti-cancer drugs approved in China from 2000 to 2024. Methods: We conducted a cross‑sectional review of 74 novel multi-indication anti-cancer drugs approved by the National Medical Products Administration (NMPA) in China from 2000 to 2024, encompassing 265 total indications. Data were collected from multiple sources, including the NMPA, the Center for Drug Evaluation (CDE) of the NMPA, the National Healthcare Security Administration (NHSA), ClinicalTrials.gov, and drug package inserts. Descriptive statistics and Fisher's exact test (two-tailed) or the Results: Of the 74 drugs, 32 (43%) held two indications, 23 (31%) held three, and 19 (26%) held four or more. Solid tumors accounted for 80% of all indications, most commonly non-small cell lung cancer. Immune checkpoint inhibitors (ICIs) exhibited the greatest expansion, with the most extensively approved drug reaching 14 indications. However, the inclusion of these drugs in the National Reimbursement Drug List (NRDL) did not keep pace with their market approval. Sequential approvals across indications showed significant differences in treatment type (P<0.001), NMPA approval type (P=0.008), trial arms (P=0.009), trial design (P=0.030), and single-arm endpoints (P<0.001). Conclusion: Regulatory reforms facilitated the approval of novel multi-indication anti-cancer drugs, although NRDL inclusion has not kept pace. Targeted therapies dominate, while ICIs, though fewer, show the broadest indication expansion. Most drugs are approved for two to three indications, mainly in solid tumors, and later approvals were associated with different regulatory pathways than earlier ones.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.